278 related articles for article (PubMed ID: 17363609)
21. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.
Watanabe D; Goshima F; Mori I; Tamada Y; Matsumoto Y; Nishiyama Y
J Dermatol Sci; 2008 Jun; 50(3):185-96. PubMed ID: 18226503
[TBL] [Abstract][Full Text] [Related]
22. Poliovirus-induced apoptosis is reduced in cells expressing a mutant CD155 selected during persistent poliovirus infection in neuroblastoma cells.
Gosselin AS; Simonin Y; Guivel-Benhassine F; Rincheval V; Vayssière JL; Mignotte B; Colbère-Garapin F; Couderc T; Blondel B
J Virol; 2003 Jan; 77(1):790-8. PubMed ID: 12477887
[TBL] [Abstract][Full Text] [Related]
23. Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma.
Ketola A; Hinkkanen A; Yongabi F; Furu P; Määttä AM; Liimatainen T; Pirinen R; Björn M; Hakkarainen T; Mäkinen K; Wahlfors J; Pellinen R
Cancer Res; 2008 Oct; 68(20):8342-50. PubMed ID: 18922906
[TBL] [Abstract][Full Text] [Related]
24. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction.
Castriconi R; Dondero A; Corrias MV; Lanino E; Pende D; Moretta L; Bottino C; Moretta A
Cancer Res; 2004 Dec; 64(24):9180-4. PubMed ID: 15604290
[TBL] [Abstract][Full Text] [Related]
25. Engineering attenuated virus vaccines by controlling replication fidelity.
Vignuzzi M; Wendt E; Andino R
Nat Med; 2008 Feb; 14(2):154-61. PubMed ID: 18246077
[TBL] [Abstract][Full Text] [Related]
26. Treatment of solid sarcomas in immunocompetent mice with novel, oncolytic herpes simplex viruses.
Sugiura S; Goshima F; Takakuwa H; Sata T; Nakashima T; Nishiyama Y
Otolaryngol Head Neck Surg; 2004 Apr; 130(4):470-8. PubMed ID: 15100647
[TBL] [Abstract][Full Text] [Related]
27. A Transgenic Mouse Model of Poliomyelitis.
Koike S; Nagata N
Methods Mol Biol; 2016; 1387():129-44. PubMed ID: 26983733
[TBL] [Abstract][Full Text] [Related]
28. [Selective resistance of human neuroblastoma cells to a vaccine strain of poliomyelitis virus].
Tol'skaia EA; Kolesnikova MS; Drozdov SG; Agol VI
Dokl Akad Nauk SSSR; 1989; 305(4):987-9. PubMed ID: 2546724
[No Abstract] [Full Text] [Related]
29. The adhesion receptor CD155 determines the magnitude of humoral immune responses against orally ingested antigens.
Maier MK; Seth S; Czeloth N; Qiu Q; Ravens I; Kremmer E; Ebel M; Müller W; Pabst O; Förster R; Bernhardt G
Eur J Immunol; 2007 Aug; 37(8):2214-25. PubMed ID: 17621371
[TBL] [Abstract][Full Text] [Related]
30. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus.
Zhang Q; Yu YA; Wang E; Chen N; Danner RL; Munson PJ; Marincola FM; Szalay AA
Cancer Res; 2007 Oct; 67(20):10038-46. PubMed ID: 17942938
[TBL] [Abstract][Full Text] [Related]
31. Mutation of a single conserved nucleotide between the cloverleaf and internal ribosome entry site attenuates poliovirus neurovirulence.
De Jesus N; Franco D; Paul A; Wimmer E; Cello J
J Virol; 2005 Nov; 79(22):14235-43. PubMed ID: 16254358
[TBL] [Abstract][Full Text] [Related]
32. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice.
Ganesh S; Gonzalez Edick M; Idamakanti N; Abramova M; Vanroey M; Robinson M; Yun CO; Jooss K
Cancer Res; 2007 May; 67(9):4399-407. PubMed ID: 17483354
[TBL] [Abstract][Full Text] [Related]
33. Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells.
Walton RW; Brown MC; Sacco MT; Gromeier M
J Virol; 2018 Oct; 92(19):. PubMed ID: 29997212
[TBL] [Abstract][Full Text] [Related]
34. Intergeneric poliovirus recombinants for the treatment of malignant glioma.
Gromeier M; Lachmann S; Rosenfeld MR; Gutin PH; Wimmer E
Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6803-8. PubMed ID: 10841575
[TBL] [Abstract][Full Text] [Related]
35. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses.
Varghese S; Rabkin SD; Nielsen GP; MacGarvey U; Liu R; Martuza RL
Cancer Res; 2007 Oct; 67(19):9371-9. PubMed ID: 17909046
[TBL] [Abstract][Full Text] [Related]
36. CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma.
Johnson BD; Jing W; Orentas RJ
J Immunother; 2007; 30(2):203-14. PubMed ID: 17471167
[TBL] [Abstract][Full Text] [Related]
37. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
38. Efficient delivery of circulating poliovirus to the central nervous system independently of poliovirus receptor.
Yang WX; Terasaki T; Shiroki K; Ohka S; Aoki J; Tanabe S; Nomura T; Terada E; Sugiyama Y; Nomoto A
Virology; 1997 Mar; 229(2):421-8. PubMed ID: 9126254
[TBL] [Abstract][Full Text] [Related]
39. Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study.
García-Castro J; Alemany R; Cascalló M; Martínez-Quintanilla J; Arriero Mdel M; Lassaletta A; Madero L; Ramírez M
Cancer Gene Ther; 2010 Jul; 17(7):476-83. PubMed ID: 20168350
[TBL] [Abstract][Full Text] [Related]
40. Practical development of genetically engineered animals as human disease models.
Nomura T
Lab Anim Sci; 1997 Apr; 47(2):113-7. PubMed ID: 9150486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
